Shares of Simulations Plus (SLP), a leading provider of biosimulation and intelligence solutions for the biopharma industry, plummeted 9.61% in pre-market trading on Thursday. The sharp decline comes on the heels of the company's significant downward revision of its fiscal 2025 revenue forecast and a lowered price target from an analyst firm.
In a surprising turn of events, Simulations Plus announced that it now expects fiscal 2025 revenue to be between $76 million and $80 million, a substantial reduction from its previous outlook of $90 million to $93 million. The company also projected its fiscal Q3 revenue to fall between $19 million and $20 million, well below the $22.8 million consensus estimate from analysts polled by FactSet. This drastic cut in revenue expectations has clearly shaken investor confidence, leading to the pre-market sell-off.
Adding to the bearish sentiment, Stephens, a prominent financial services firm, lowered its price target on Simulations Plus from $42 to $28. Despite maintaining an Overweight rating on the stock, this significant reduction in the price target suggests concerns about the company's near-term growth prospects. The combination of reduced revenue guidance and the lowered price target has created a perfect storm, driving the stock's pre-market plunge as investors reassess their positions in light of these developments.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.